RAD52 and neoplasm: In concordance with these observations, another study performed by Sullivan-Reed et al. showed that the simultaneous targeting of PARP1 and RAD52 genes exerted a synergistic action by trigging a dual synthetic lethality in BRCA-deficient tumor cells.